Influenza Virus

Our team at IBT Bioservices has extensive experience in preclinical testing services to assess the viability and effectiveness of novel therapies against respiratory illnesses such as RSV, influenza, SARS-CoV-2 through animal models and cell-based assays.



Antigenic Variation

Undergo constant antigenic changes, leading to the need for seasonal flu vaccines to match the circulating strains.


Mild to severe respiratory infection


Orthomyxoviridae family and are classified into types A, B, C, and D.

IBT Bioservices has developed an extensive assortment of reagents to facilitate the advancement of therapeutics and assay development, thus supporting the progress of research on Influenza. We offer a diverse array of products and services designed to facilitate Influenza research, ranging from viral proteins to antiserum and antibodies.

Our comprehensive range of products includes


Purified monoclonal and polyclonal antibodies

Recombinant proteins

Rest assured, our reagents are of exceptional quality, and they are available for purchase to support your research endeavors.

Our preclinical testing services for influenza encompass a wide range of assessments, including:

Antiviral Screening

Our in vitro influenza services include antiviral screening assays to identify potential candidates with antiviral activity against influenza viruses. We utilize high-throughput screening techniques to evaluate large compound libraries, natural products, or novel drug candidates for their ability to inhibit viral replication. Our screening assays enable the identification of lead compounds with promising antiviral properties for further development.

Our Services

  1. CPE Inhibition Assay
  2. Microneutralization
  3. Assay
  4. PRNT
  5. Hemagglutination
  1. Inhibition Assay
  2. qPCR
  3. Plaque Assay
  4. TCID50
  5. Yield Reduction Assay
  1. Yield Reduction Assay
  2. Cell-based ELISA
  3. Influenza Virus Characterization
  4. Animal Models

Vaccine Evaluation

Our in vivo influenza services include vaccine evaluation studies using animal models. We assess the immunogenicity and protective efficacy of influenza vaccine candidates, helping you determine their ability to induce robust immune responses and provide protection against circulating influenza strains. Our services support the development and optimization of influenza vaccines with enhanced efficacy and broader strain coverage.


We offer a range of rodent animal models for studying influenza virus infection, pathogenesis, and evaluating the efficacy of potential interventions. Our animal models closely mimic the clinical and immunological aspects of influenza infection in humans, providing valuable insights into viral replication, host immune responses, disease progression, and treatment outcomes. Animal Species and Strains: Balb/c Mice, C57BL/6 Mice

IBT has established both in vitro and in vivo models using a diverse range of influenza virus strains. We also offer a selection of mouse-adapted virus strains and custom services for developing a lethal model.

Influenza A (H1N1): A/Texas/36/91, A/Ca/07/09, A/PR/8/34, A/Perth261/2009- H275Y, A/Miss/3/2001,

Influenza A (H3N2): A/Hong Kong/1/68, A/Victoria/3/75

Influenza B, Victoria Lineage: B/Brisbane/60/09

Influenza B, Yamagata Lineage: B/Florida/04/06

Influenza B, B/Lee/40

When conducting efficacy studies for influenza in rodents, it is essential to consider certain factors.

Animal Strain Selection

While wild mice are highly resistant, inbred laboratory mouse strains such as BALB/c and C57BL/6 mice are susceptible to a variety of influenza viruses.

Formulation and Treatment Route

Determining the ideal treatment route and regimen for your therapeutic route is vital to determine the potency of your therapeutic and its ability to inhibit viral replication.

Proper formulation of drug candidates and vaccines are crucial to determine their effectiveness. Including appropriate controls can help identify the enhancing effects of the drug or additives or if they provide protection.

Therapeutic Target and Virus Strain

Selection of virus strain based on the therapeutics method of action and target 

Endpoint Assays and Readouts

Collection of affected organs for evaluating viral load, cellular immune response, and histopathology.

Animal survival, weight change percentage, and clinical appearance

The mouse offers a convenient and efficient model for lead identification and preclinical analysis of safety and efficacy. The highly characterized murine system offers a reliable model for evaluating various immunological parameters to address vaccine design and candidate evaluation. While wild mice are highly resistant, inbred laboratory mouse strains such as Balb/C and C57BL/6 mice are susceptible to a variety of influenza viruses. Some strains can cause disease in mice without adaptation but for seasonal H1N1 and H3N2 strains adaptation is required. Changes in body weight, health score and mortality are used to evaluate efficacy of treatments and vaccines against specific strains.

Female BALB/c mice were treated with two antibodies 24-hours before inoculation with 1.00E+05 PFU/animal of Influenza B/Florida/04/2006 (Yamagata lineage) via the intranasal (IN) route. The mean time of death for this virus strain falls on day 7.

At IBT, we offer a wide range of specialized services and expertise in influenza research. Our experienced team of scientists and researchers provide high-quality data, reliable results, and customized solutions to meet your specific research needs. Whether you require in vivo studies to evaluate vaccine candidates or in vitro assays to screen antiviral compounds, we are here to support your influenza research and development efforts.Contact us today to discuss your specific influenza service requirements and discover how our expertise can accelerate your research, advance influenza interventions, and contribute to global efforts in combating influenza viruses.